Trial Profile

A First-In-Human, Open Label, Dose Escalation Trial to Evaluate the Safety, Tolerability and Pharmacodynamics of a Single Dose of AXV-101 in Patients With Bardet-Biedl Syndrome 1 (BBS1) Bi-Allelic Mutations and Retinal Degeneration

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 07 Aug 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

04 Aug 2026 Status changed from not yet recruiting to recruiting.
31 Mar 2026 Planned initiation date changed from 23 Feb 2026 to 1 May 2026.
06 Jan 2026 According to Axovia Therapeutics media release, the company has received $1.1 million funding A Race Against Blindness ,to support this study .the study is expected expected to begin in early 2026.This latest funding brings A Race Against Blindnesss total commitment for AXV-101 to $5.1 million.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com